Abstract:Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the production of primary prostanoids by blocking the access of arachidonic acid to the active site of the cyclooxygenases (COXs). Because the prostanoids produced by COX-1 appear to play a physiological role (protection of the gastric mucosa, platelet aggregation, vascular homeostasis, maintenance of renal sodium-water balance) while those produced by COX-2 seem mainly to intervene in the inflammatory response and in certain processes associated with cell proliferation, the hypothesis has been put forward that the NSAIDs that are selective COX-2 inhibitors should theoretically be capable of maintaining NSAID therapeutic properties but also have fewer adverse side effects due to the maintenance of prostaglandin production at normal physiological levels. Current knowledge and key points: The hypothesis of COX isoenzyme selectivity has led to a proposed classification for COX inhibitors: 1) COX-1 selective inhibitors (low-dosage aspirin); 2) COX non-selective inhibitors (the majority of classified NSAIDs, which when administered over the long term, e.g., in cases of rheumatoid arthritis, cause duodenal ulcers in 20% of cases and gastric hemorrhage in 1-4% of cases/year); 3) COX-2 preferential inhibitors (meloxicam and nimesulide, which have fewer gastric side effects than standard NSAIDs, but which are not risk-free at high doses); 4) COX-2 selective inhibitors (celecoxib and rofecoxib). Preliminary clinical studies have shown that COX-2 selective inhibitors are as efficient as standard NSAIDs and have fewer adverse digestive side effects, thereby confirming the interest of this proposed classification. In the UK, the aforementioned studies have led to the commercialization of rofecoxib for the treatment of pain and osteoarthritis, while celecoxib has been introduced in medical practice in the USA and other countries for the treatment of rheumatoid arthritis and osteoarthritis. Future prospects and projects: Various epidemiological and laboratory studies have indicated that NSAIDs may be able to reduce the risk of cancer (colorectal cancer in particular) and Alzheimer's disease due to their inhibitory activity on COXs, especially COX-2. The therapeutic contribution of COX-2 specific inhibitors has to be more fully evaluated, particularly as these agents could delay the healing of duodenal ulcers and interfere with several COX-2-induced physiological functions. It is therefore suggested that until further information becomes available, this new class of NSAIDs should be used with caution in certain patient populations.

Progress in research of COX-2,a target for new NSAIDs development

Recent Research Advances of Nonsteroidal Anti-Inflammatory Drugs (Nsaids)

Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years

Advances in Selective COX-2 Inhibitors

Recent Development of Nonsteroidal Antiinflammatory Drugs in the Field of Dual COX/5-LOX Inhibitors

Advances in the Research on the Cyclooxygenase-2 and 5-Lipoxygenase Dual Inhibitors

[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]

Cyclooxygenase:A New Target in Development of Drugs

Recent advancement in the discovery and development of COX-2 inhibitors: Insight into biological activities and SAR studies (2008-2019)

Research Progress in Cyclooxygenase and its Inhibitors

The Second Generation of COX-2 Inhibitors

A Novel Class of Anti-Inflammatory and Analgesic Drugs——no-Donating NSAIDs

Safety and rational choice of non-steroidal anti-inflammatory drugs

Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects

Natural COX-2 Inhibitors As Promising Anti-Inflammatory Agents: an Update.

Design, synthesis, and biological evaluation of dual-target COX-2/5-LOX inhibitors for the treatment of inflammation

Advances in Research on COX-2 Inhibitors as Antitumor Drugs

Design, synthesis and structure–activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs

Molecular Mechanism for COX-2 in Carcinogenesis

Dual-target Inhibitors Based on COX-2: a Review from Medicinal Chemistry Perspectives.

Design and Development of COX-II Inhibitors: Current Scenario and Future Perspective